Global Action Fund for Fungal Infections

Last updated
GAFFI Master LOGO electronic - RGB.jpg
Global Action For Fungal Infections
AbbreviationGAFFI
Purpose
  • Raise awareness of and collect data on fungal disease
  • To make reliable and inexpensive diagnostic tests widely available
Location
  • Geneva, Switzerland
  • Altrincham, Cheshire, United Kingdom
FieldsFungal disease
Board Chair
Oddi Aasheim
Website Official website

The Global Action For Fungal Infections(GAFFI), is an international foundation focussed on raising awareness of and collecting worldwide data on fungal disease. Its aim is to make reliable and inexpensive diagnostic tests widely available.

Contents

In 2015, GAFFI proposed action to make affordable fungal diagnostic tests and antifungal treatments available to 95% of the world's population by 2025. In 2018 GAFFI calculated that globally around one billion people have fungal infections of the skin, more than one million people become blind from fungal keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more than 300 million people have a severe fungal infection every year, of whom over 1.5 million die.

Location and members

The GAFFI is based in Switzerland and the United Kingdom. Its Board Chair is Oddi Aasheim.

Aims

GAFFI is an international foundation focussed on raising awareness of and collecting worldwide data on fungal disease burden. Its primary aims are to get reliable and inexpensive diagnostic tests to be widely available, particularly in low and middle income countries. The tests can be produced but the increasing cost of regulatory approval causes difficulty in getting them from the experimental stage in the laboratory to real world use in clinics.

Activities

GAFFI has successfully advocated for multiple diagnostics as Essential to be listed on the World Health Organization's EDL. GAFFI tracks country registration and access to Essential Medicines for antifungal agents. GAFFI also estimates and publicises data on fungal diseases incidence and prevalence (burden).

The GAFFI was launched in London in 2013. In 2015, GAFFI proposed action to make fungal diagnostic tests and antifungal treatments available to 95% of the world's population by 2025 95/95 by 2025. Six actions were proposed:

In 2018 the GAFFI calculated that globally around one billion people every year have fungal infections of the skin, more than one million people become blind from fungal keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more than 300 million people have severe fungal infections, of which over 1.5 million will die from it. [3]

In 2022, GAFFI published a report on access to diagnostics in 49 African countries, with the Africa Centre for Disease Control and Prevention. Many gaps remain.

Related Research Articles

<span class="mw-page-title-main">Coccidioidomycosis</span> Fungal infection

Coccidioidomycosis, commonly known as cocci, Valley fever, as well as California fever, desert rheumatism, or San Joaquin Valley fever, is a mammalian fungal disease caused by Coccidioides immitis or Coccidioides posadasii. Coccidioidomycosis is endemic in certain parts of the United States in Arizona, California, Nevada, New Mexico, Texas, Utah, and northern Mexico.

<span class="mw-page-title-main">Pleurisy</span> Disease of the lungs

Pleurisy, also known as pleuritis, is inflammation of the membranes that surround the lungs and line the chest cavity (pleurae). This can result in a sharp chest pain while breathing. Occasionally the pain may be a constant dull ache. Other symptoms may include shortness of breath, cough, fever, or weight loss, depending on the underlying cause. Pleurisy can be caused by a variety of conditions, including viral or bacterial infections, autoimmune disorders, and pulmonary embolism.

<span class="mw-page-title-main">Cryptococcosis</span> Potentially fatal fungal disease

Cryptococcosis is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and brain, where it appears as a meningitis. Cough, difficulty breathing, chest pain and fever are seen when the lungs are infected. When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity and confusion or changes in behavior. It can also affect other parts of the body including skin, where it may appear as several fluid-filled nodules with dead tissue.

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Fungal infection</span> Disease caused by fungi to animals or humans

Fungal infection, also known as mycosis, is a disease caused by fungi. Different types are traditionally divided according to the part of the body affected; superficial, subcutaneous, and systemic. Superficial fungal infections include common tinea of the skin, such as tinea of the body, groin, hands, feet and beard, and yeast infections such as pityriasis versicolor. Subcutaneous types include eumycetoma and chromoblastomycosis, which generally affect tissues in and beneath the skin. Systemic fungal infections are more serious and include cryptococcosis, histoplasmosis, pneumocystis pneumonia, aspergillosis and mucormycosis. Signs and symptoms range widely. There is usually a rash with superficial infection. Fungal infection within the skin or under the skin may present with a lump and skin changes. Pneumonia-like symptoms or meningitis may occur with a deeper or systemic infection.

<span class="mw-page-title-main">Dermatophytosis</span> Fungal infection of the skin

Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a red, itchy, scaly, circular rash. Hair loss may occur in the area affected. Symptoms begin four to fourteen days after exposure. Multiple areas can be affected at a given time.

<span class="mw-page-title-main">Fungal pneumonia</span> Infection of the lungs by fungi

Fungal pneumonia is an infection of the lungs by fungi. It can be caused by either endemic or opportunistic fungi or a combination of both. Case mortality in fungal pneumonias can be as high as 90% in immunocompromised patients, though immunocompetent patients generally respond well to anti-fungal therapy.

<span class="mw-page-title-main">Sporotrichosis</span> Medical condition

Sporotrichosis, also known as rose handler's disease, is a fungal infection that may be localised to skin, lungs, bone and joint, or become systemic. It presents with firm painless nodules that later ulcerate. Following initial exposure to Sporothrix schenckii, the disease typically progresses over a period of a week to several months. Serious complications may develop in people who have a weakened immune system.

<span class="mw-page-title-main">Allergic bronchopulmonary aspergillosis</span> Medical condition

Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterised by an exaggerated response of the immune system to the fungus Aspergillus. It occurs most often in people with asthma or cystic fibrosis. Aspergillus spores are ubiquitous in soil and are commonly found in the sputum of healthy individuals. A. fumigatus is responsible for a spectrum of lung diseases known as aspergilloses.

Fungal keratitis is a fungal infection of the cornea, which can lead to blindness. It generally presents with a red, painful eye and blurred vision. There is also increased sensitivity to light, and excessive tears or discharge.

<span class="mw-page-title-main">Aspergillosis</span> Medical condition

Aspergillosis is a fungal infection of usually the lungs, caused by the genus Aspergillus, a common mould that is breathed in frequently from the air, but does not usually affect most people. It generally occurs in people with lung diseases such as asthma, cystic fibrosis or tuberculosis, or those who are immunocompromized such as those who have had a stem cell or organ transplant or those who take medications such as steroids and some cancer treatments which suppress the immune system. Rarely, it can affect skin.

<span class="mw-page-title-main">Paracoccidioidomycosis</span> Medical condition

Paracoccidioidomycosis (PCM), also known as South American blastomycosis, is a fungal infection that can occur as a mouth and skin type, lymphangitic type, multi-organ involvement type (particularly lungs), or mixed type. If there are mouth ulcers or skin lesions, the disease is likely to be widespread. There may be no symptoms, or it may present with fever, sepsis, weight loss, large glands, or a large liver and spleen.

<span class="mw-page-title-main">Conidiobolomycosis</span> Fungal infection

Conidiobolomycosis is a rare long-term fungal infection that is typically found just under the skin of the nose, sinuses, cheeks and upper lips. It may present with a nose bleed or a blocked or runny nose. Typically there is a firm painless swelling which can slowly extend to the nasal bridge and eyes, sometimes causing facial disfigurement.

<i>Cochliobolus lunatus</i> Fungal plant pathogen

Cochliobolus lunatus is a fungal plant pathogen that can cause disease in humans and other animals. The anamorph of this fungus is known as Curvularia lunata, while C. lunatus denotes the teleomorph or sexual stage. They are, however, the same biological entity. C. lunatus is the most commonly reported species in clinical cases of reported Cochliobolus infection.

<span class="mw-page-title-main">Clotrimazole</span> Chemical compound

Clotrimazole, sold under the brand name Lotrimin, among others, is an antifungal medication. It is used to treat vaginal yeast infections, oral thrush, diaper rash, tinea versicolor, and types of ringworm including athlete's foot and jock itch. It can be taken by mouth or applied as a cream to the skin or in the vagina.

<span class="mw-page-title-main">Mucormycosis</span> Fungal infection

Mucormycosis, also known as black fungus, is a serious fungal infection that comes under fulminant fungal sinusitis, usually in people who are immunocompromised. It is curable only when diagnosed early. Symptoms depend on where in the body the infection occurs. It most commonly infects the nose, sinuses, eyes and brain resulting in a runny nose, one-sided facial swelling and pain, headache, fever, blurred vision, bulging or displacement of the eye (proptosis), and tissue death. Other forms of disease may infect the lungs, stomach and intestines, and skin.

Invasive candidiasis is an infection (candidiasis) that can be caused by various species of Candida yeast. Unlike Candida infections of the mouth and throat or vagina, invasive candidiasis is a serious, progressive, and potentially fatal infection that can affect the blood (fungemia), heart, brain, eyes, bones, and other parts of the body.

<i>Epidermophyton floccosum</i> Species of fungus

Epidermophyton floccosum is a filamentous fungus that causes skin and nail infections in humans. This anthropophilic dermatophyte can lead to diseases such as tinea pedis, tinea cruris, tinea corporis and onychomycosis. Diagnostic approaches of the fungal infection include physical examination, culture testing, and molecular detection. Topical antifungal treatment, such as the use of terbinafine, itraconazole, voriconazole, and ketoconazole, is often effective.

<span class="mw-page-title-main">Tania Sorrell</span> Australian infectious disease physician

Tania Sorrell is an Australian infectious disease physician who is a Professor and Director of the Marie Bashir Institute for Infectious Diseases and Biosecurity at the University of Sydney. She serves as Chair of the National Health and Medical Research Council Research Translation Faculty Steering Group on New and Emerging Health Threats. She is interested in the diagnosis, prevention and treatment of infectious diseases.

David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at the University of Manchester. He was the founding president, executive director and chief executive of Global Action For Fungal Infections (GAFFI) (2013-2023), which focusses on the global impact of fungal disease.

References

  1. 1 2 3 4 5 6 Denning, David W. (1 July 2015). "The ambitious '95–95 by 2025' roadmap for the diagnosis and management of fungal diseases". Thorax. 70 (7): 613–614. doi: 10.1136/thoraxjnl-2015-207305 . ISSN   0040-6376. PMID   26024686. S2CID   2406405.
  2. Gadd, Geoffrey M.; Sariaslani, Sima (June 2020). Advances in Applied Microbiology. Elsevier. p. 39. ISBN   978-0-12-820703-1.
  3. Rodrigues, Marcio L.; Nosanchuk, Joshua D. (20 February 2020). "Fungal diseases as neglected pathogens: A wake-up call to public health officials". PLOS Neglected Tropical Diseases. 14 (2): e0007964. doi: 10.1371/journal.pntd.0007964 . ISSN   1935-2735. PMC   7032689 . PMID   32078635.